Follow the DENTSPLY SIRONA Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, DENTSPLY SIRONA Inc. has published 532 insider filings. Market capitalisation: €2.3bn. The latest transaction was filed on 16 June 2026 (Acquisition). Among the most active insiders: LUCIER GREGORY T. The full history is accessible without an account.
Analysts rate DENTSPLY SIRONA Inc. Hold (neutral), based on 15 analysts. Average price target: US$13.40.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 532 declarations
DENTSPLY SIRONA Inc. (ticker: XRAY) is a U.S.-listed dental technology and consumables company traded on the Nasdaq in the United States. For investors, it sits at the intersection of healthcare, medical devices, and dental workflow technology, with exposure to recurring consumables as well as more capital-intensive equipment and digital imaging systems. The company’s global headquarters is in Charlotte, North Carolina, a relevant detail for European investors following U.S. healthcare names. ([investor.dentsplysirona.com](https://investor.dentsplysirona.com/news-releases/news-release-details/dentsply-sirona-reports-fourth-quarter-and-full-year-2024/?utm_source=openai)) The company’s heritage reflects the combination of two established dental businesses: DENTSPLY, whose roots go back to the late 19th century, and Sirona, a German dental equipment and imaging specialist. Their merger created a broader platform spanning the consumables, equipment, and software layers of the dental ecosystem. Dentsply Sirona emphasizes its international footprint, distributing products in more than 150 countries, which gives it wide market reach but also exposes it to foreign exchange, regional demand cycles, and competitive intensity. ([fintel.io](https://fintel.io/doc/sec-dentsply-sirona-inc-818479-10k-2024-february-29-19782-244?utm_source=openai)) Operationally, the group offers a diversified portfolio across restorative dentistry, endodontics, implants and prosthetics, orthodontics, imaging and diagnostics, dental chairside equipment, and connected digital workflow solutions. Its competitive position is built on breadth of product range, long-standing brand recognition, installed base relationships, and the ability to bundle hardware, consumables, and software into integrated clinical workflows. Strategically, that matters because dentistry is increasingly shaped by digital tools, 3D imaging, and efficiency-focused practice management. ([investor.dentsplysirona.com](https://investor.dentsplysirona.com/static-files/0d4ca110-18df-4dcc-85d4-ca53822531c8?utm_source=openai)) Dentsply Sirona remains a global business with a meaningful presence in North America, Europe, and other international markets. In 2024, the company employed approximately 4,600 people and continued to optimize its geographic footprint to improve efficiency. For investors, that suggests a mature operating base with global diversification, but also a need for disciplined execution in a slower-growth end market. ([investor.dentsplysirona.com](https://investor.dentsplysirona.com/static-files/0d4ca110-18df-4dcc-85d4-ca53822531c8?utm_source=openai)) Recent developments have been important. Fiscal 2024 included material non-cash impairment charges tied to orthodontics, implants, and connected technology, reflecting weaker demand and competitive pressure in some categories. In 2025 and 2026, the company went through notable leadership changes: Dan Scavilla was appointed CEO, Matt Garth became CFO, and the business launched a “Return-to-Growth” action plan aimed at sharpening commercial execution, improving the customer experience, and optimizing capital allocation. In October 2025, Dentsply Sirona also disclosed that the SEC investigation opened in May 2022 had concluded and that the SEC did not intend to take enforcement action. ([investor.dentsplysirona.com](https://investor.dentsplysirona.com/news-releases/news-release-details/dentsply-sirona-reports-fourth-quarter-and-full-year-2024/?utm_source=openai))